Condition
Transplant Associated Microangiopathy TAM
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Terminated1
Not Yet Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07381205Not Yet RecruitingPrimary
Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)
NCT06715046Recruiting
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
NCT02763644Phase 2TerminatedPrimary
Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
Showing all 3 trials